(Q33860794)

29 July 2017

1 reference

title

Dermatomyositis after interferon alpha treatment (English)

1 reference

29 July 2017

0 references

Dietrich LL

1

1 reference

29 July 2017

Bridges AJ

series ordinal

2

1 reference

29 July 2017

Albertini MR

series ordinal

3

1 reference

29 July 2017

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

1

1 reference

29 July 2017

64-69

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02826219

29 July 2017

0 references

cites work

Quantitative histopathology of the inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1007%2FBF02826219

Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02826219

Dermatomyositis and malignancy. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02826219

Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02826219

Rheumatoid Arthritis-like Disease after Alpha-Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02826219

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies

21 January 2018

1 reference

12 December 2020

Lupus activity criteria count

1 reference

12 December 2020

Elevated cancer incidence in patients with dermatomyositis: a population based study

1 reference

12 December 2020

Vascular Deposits of Immunoglobulin and Complement in Idiopathic Inflammatory Myopathy

1 reference

12 December 2020

Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study

1 reference

12 December 2020

Immunologic aspects of myositis

1 reference

12 December 2020

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

12 December 2020

Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon

1 reference

12 December 2020

Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon

1 reference

12 December 2020

Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients

1 reference

12 December 2020

Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies

1 reference

12 December 2020

Progressive glomerulonephritis in mice treated with interferon preparations at birth

1 reference

12 December 2020

Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes

1 reference

12 December 2020

A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases

1 reference

12 December 2020

Biochemistry of Interferons and Their Actions

1 reference

12 December 2020

Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease

1 reference

12 December 2020

Lymphokines in autoimmunity--a critical review

1 reference

12 December 2020

Dermatomyositis and malignant melanoma

1 reference

12 December 2020

Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis

1 reference

12 December 2020

Differential effects of recombinant human leukocyte interferons on cell surface antigen expression

1 reference

12 December 2020

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders

1 reference

12 December 2020

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

1 reference

12 December 2020

Serum levels of interferons in patients with systemic lupus erythematosus

1 reference

12 December 2020

The overall and temporal association of cancer with polymyositis and dermatomyositis

1 reference

12 December 2020

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

12 December 2020

The Jo-1 antibody system in myositis: relationships to clinical features and HLA.

1 reference

12 December 2020

Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment

1 reference

12 December 2020

Interferon treatment of NZB mice: accelerated progression of autoimmune disease

1 reference

12 December 2020

Immune mechanisms in myositis.

1 reference

12 December 2020

Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease

1 reference

12 December 2020

Dermatomyositis and metastatic malignant melanoma, with complete regression of the primary lesion

1 reference

12 December 2020

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

1 reference

12 December 2020

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

12 December 2020

Dermatomyositis associated with malignant melanoma. Parallel occurrence, remission, and relapse of the two processes in a patient

1 reference

12 December 2020

Interferons and their actions

1 reference

12 December 2020

Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes

1 reference

12 December 2020

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

12 December 2020

Immune thrombocytopenia following alpha-interferon therapy in patients with cancer

1 reference

12 December 2020

Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis

1 reference

12 December 2020

Serum interferon levels in patients with systemic lupus erythematosus

1 reference

12 December 2020

Digital vasculitis associated with interferon therapy

1 reference

12 December 2020

Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells

1 reference

12 December 2020

Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

1 reference

12 December 2020

Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha

1 reference

12 December 2020

Dermatomyositis associated with malignant melanoma--case report and review of the literature

1 reference

12 December 2020

Effects of interferon-alpha on the expression of a lupus idiotype in normal humans

1 reference

12 December 2020

Myositis and malignancy.

1 reference

12 December 2020

Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis

1 reference

12 December 2020

Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02826219

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference